John T. Monyak
YOU?
Author Swipe
View article: Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension Open
Key Points This phase 2 trial assessed baxdrostat, an aldosterone synthase inhibitor, in participants with CKD and uncontrolled hypertension. Baxdrostat showed placebo-corrected reduction in systolic BP of –8.1 (95% confidence interval –13…
View article: Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)
Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up) Open
Context The T2NOW trial of dapagliflozin or saxagliptin vs placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety concerns over 52 weeks. Objective This …
View article: Once-Weekly Exenatide in Youth With Type 2 Diabetes
Once-Weekly Exenatide in Youth With Type 2 Diabetes Open
OBJECTIVE: Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately half of the youth fail metformin monotherapy within 1 year, and insulin therapy is associated with…
View article: Once-Weekly Exenatide in Youth With Type 2 Diabetes
Once-Weekly Exenatide in Youth With Type 2 Diabetes Open
OBJECTIVE: Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately half of the youth fail metformin monotherapy within 1 year, and insulin therapy is associated with…
View article: Once-Weekly Exenatide in Youth With Type 2 Diabetes
Once-Weekly Exenatide in Youth With Type 2 Diabetes Open
OBJECTIVE Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately one-half of the youth fail metformin monotherapy within 1 year, insulin therapy is associated with …